Skip to main content

Table 2 Baseline characteristics and treatment information

From: Comparative effects of recombinant human brain natriuretic peptide and dobutamine on acute decompensated heart failure patients with differsent blood BNP levels

Characteristics

High BNP group

Extra-high BNP group

 

Dobutamine (n = 30)

rhBNP (n = 28)

P value

Dobutamine (n = 23)

rhBNP (n = 23)

P value

Age (y)

63 ± 13

65 ± 13

0.495†

68 ± 14

67 ± 12

0.709†

Male/female

19/11

18/10

0.843‡

15/8

16/7

0.935‡

HF etiology

 IDC

13

11

0.963‡

10

12

0.768‡

 CHD

8

10

0.645‡

10

8

0.763‡

 FVM

2

1

1.000§

0

1

1.000§

 HHD

1

2

0.605§

0

1

1.000§

 Valvulopathy

6

4

0.732§

3

1

0.608§

 NHYA

  

0.645‡

  

0.489§

 III

8

10

 

0

2

 

 IV

22

18

 

23

21

 

Concomitant medications

 ACEI

14

16

0.593‡

14

12

0.766‡

 ARB

12

7

0.349‡

5

8

0.513‡

 Digitalis

24

23

0.899‡

18

20

0.699§

 β-blockers

11

14

0.448‡

4

6

0.722§

Spironolactone

 20 (mg/d)

15

18

0.405‡

11

6

0.324‡

 40 (mg/d)

10

8

0.914‡

10

12

0.768‡

Average dosage

28.0 ± 10.0

26.2 ± 9.4

0.500†

29.5 ± 10.2

33.3 ± 9.7

0.243†

Furosemide (mg/d)

 20 (mg/d)

12

15

0.440‡

7

4

0.328§

 40 (mg/d)

11

8

0.707‡

11

9

0.766‡

 80 (mg/d)

2

3

0.665§

3

5

0.699§

 Average dosage

33.6 ± 17.0

33.1 ± 19.5

0.919†

39.0 ± 19.5

46.7 ± 22.8

0.267†

  1. †Unpaired t-test; ‡Chi-square test; §Fisher exact test.
  2. Abbreviations: ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, BNP brain natriuretic peptide, CHD coronary heart disease, HF heart failure, HHD hyperthyroid heart disease, IDC idiopathic dilated cardiomyopathy, NHYA New York Heart Association, rhBNP recombinant human brain natriuretic peptide. Values are expressed as number or mean ± SD.
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us